Literature DB >> 920225

Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic.

H A Amsler, L Teerenhovi, E Barth, K Harjula, P Vuopio.   

Abstract

The occurrence of a sudden outbreak of agranulocytosis in Finland among patients being treated with clozapine led to intensive investigations in an attempt to find a local precipitating factor. Granulocytopenia after clozapine was found to have the same characteristics as that reported after phenothiazines. No local factor, either genetic or environmental, was found which could have been responsible for the increased frequency of occurrence in Finland. The need to be aware of the risk and to take appropriate precautionary measures (e.g. weekly leucocyte counts in the first months) is emphasized.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 920225     DOI: 10.1111/j.1600-0447.1977.tb00224.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  21 in total

Review 1.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

Review 3.  Leponex--associated granulocytopenia: a review of the situation.

Authors:  P Krupp; P Barnes
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients.

Authors:  D Naber; M Leppig; R Grohmann; H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Continuing clozapine treatment despite neutropenia.

Authors:  David Esposito; Frédéric Rouillon; Frédéric Limosin
Journal:  Eur J Clin Pharmacol       Date:  2004-11-30       Impact factor: 2.953

Review 6.  Clinical experience with clozapine in Germany.

Authors:  H Helmchen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Safety of psychotropic medicines: contribution from observational evidence.

Authors:  H Verdoux
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-30       Impact factor: 6.892

8.  Clozapine-induced agranulocytosis.

Authors:  B Anger; S Reichert; H Heimpel
Journal:  Blut       Date:  1987-01

Review 9.  Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

Authors:  K G Terkelsen; A Menikoff
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 10.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.